Oregovomab is intended for the treatment of advanced ovarian cancer. Credit: Chinnapong/Shutterstock.com.

CanariaBio has entered into a distribution and licence agreement with Hikma MENA FZE, part of Hikma Pharmaceuticals, for oregovomab to treat advanced ovarian cancer.

Hikma MENA FZE will distribute oregovomab in the Middle East and North Africa (MENA) region.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

CanariaBio CEO Michael Na stated: “We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations.”

Oregovomab, a murine monoclonal antibody, targets the tumour-associated antigen CA125 that stimulates a host cytotoxic immune response against tumour cells that express the CA 125 biomarker.

A randomised Phase II study of oregovomab together with first-line chemotherapy showed a significant improvement in progression-free survival of 41.8 months against 12.2 months with standard chemotherapy.

It also demonstrated improvements in overall survival with a hazard ratio of 0.35.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Oregovomab along with carboplatin and paclitaxel is also being investigated in the Phase III FLORA-5 trial in patients with advanced ovarian cancer.

It received orphan drug designations from the European Medicines Agency and the US Food and Drug Administration.

Hikma executive vice-chairman and MENA president Mazen Darwazah stated: “We have been actively expanding our oncology portfolio through research and development and in-licensing, in order to address unmet medical needs in different types of cancer and bring renewed hope to cancer patients in the MENA region.

“We believe Oregovomab can potentially improve the treatment outcomes for patients with advanced primary ovarian cancer.”

In addition to the MENA region, Hikma has a presence in North America and Europe and makes its medicines accessible to those in need.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact